Overview

Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the present study is to evaluate continuous administration of low doses of VA2914 for potential contraceptive activity and effects on the menstrual cycle and steroid hormone parameters.
Phase:
Phase 2
Details
Lead Sponsor:
HRA Pharma
Treatments:
Progesterone